CymitQuimica logo

CAS 1005342-46-0

:

LCL-161

Description:
LCL-161 is a small molecule that acts as a selective inhibitor of the inhibitor of apoptosis proteins (IAPs), which are a family of proteins that regulate apoptosis (programmed cell death) and are often overexpressed in various cancers. By inhibiting IAPs, LCL-161 promotes apoptosis in cancer cells, making it a potential therapeutic agent in oncology. The compound has been studied for its ability to enhance the efficacy of other anticancer treatments, particularly in combination therapies. LCL-161 is characterized by its specific binding affinity to IAPs, leading to the activation of caspases, which are crucial enzymes in the apoptotic pathway. Additionally, it has shown promise in preclinical studies for various cancer types, including hematological malignancies and solid tumors. Its pharmacological profile includes considerations of bioavailability, metabolism, and potential side effects, which are critical for its development as a therapeutic agent. As research continues, LCL-161 may contribute to novel cancer treatment strategies, particularly in cases where traditional therapies have limited effectiveness.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.